Form 4: Theravance Biopharma Exec's Tax Withholding

A Theravance Biopharma executive disposed of shares to cover tax obligations from restricted stock unit vesting.

Summary

• Brett A. Grimaud, SVP, General Counsel and Secretary of Theravance Biopharma, Inc., disposed of 9,762 ordinary shares.
• The transaction occurred on August 20, 2025, at a price of $13.39 per share.
• These shares were withheld by the issuer to satisfy tax obligations related to the vesting of previously granted restricted stock units.
• Following this transaction, Mr. Grimaud directly beneficially owns 374,306 ordinary shares.

Sentiment

Score: 6

Explanation: The transaction is a routine tax withholding, indicating the vesting of previously granted equity, which is a positive for the executive. It's a neutral event for the company's operational performance but reflects standard compensation practices.

Positives

• The transaction indicates the vesting of previously granted restricted stock units, which is a positive event for the executive as it represents earned compensation.

Negatives

• The executive's direct beneficial ownership of ordinary shares decreased by 9,762 shares due to the tax withholding.

Industry Context

This is a routine insider transaction related to executive compensation and tax obligations, common across all industries for publicly traded companies with equity compensation plans.

Related Party Transactions

• The transaction involved the withholding of shares by the issuer (Theravance Biopharma, Inc.) from the reporting person (Brett A. Grimaud) to cover tax obligations, which is a related party transaction but a standard practice for equity compensation.

Stakeholder Impact

• **Shareholders**: Minimal direct impact as it's a routine tax-related disposition by an insider, not an open market sale. It reflects standard executive compensation practices.
• **Employees**: Reinforces the company's equity compensation structure and vesting schedules.

Key Dates

Recommendation

This Form 4 filing details a routine tax withholding transaction by an executive, which is a standard part of equity compensation vesting. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction itself is neutral to slightly positive as it confirms executive compensation vesting.

Keywords

Theravance Biopharma, TBPH, Form 4, Insider Transaction, Stock Vesting, Tax Withholding, Restricted Stock Units, Executive Compensation